Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2008

View Archived Issues

Selective immunoproteasome inhibition with PR-957 beneficial in models of rheumatoid arthritis

CBP-501 well tolerated alone and with cisplatin in phase I solid tumor studies

New phase I and II data on BIBW-2992 reported

Recent patents disclose new therapeutic agents for obesity and nutrition disorders

Efficacy of golimumab in rheumatoid arthritis demonstrated in phase III studies

Cogentus enrolls first European patient in pivotal phase III CGT-2168 trial

Exelixis and FDA agree on Special Protocol Assessment for XL-184 phase III trial

Metabolex completes patient enrollment in phase II MBX-8025 trial

JX-594 well tolerated, active in refractory primary and metastatic liver cancer

CSL receives Australian approval to register Panvax avian flu vaccine

Novartis withdraws MAA for pre-pandemic vaccine Aflunov

Humira subcutaneous injection now available in Japan for rheumatoid arthritis

ARYx Therapeutics commences phase II/III trial comparing ATI-5923 to warfarin

Genzyme files Mozobil marketing applications in the United States and Europe

Oncothyreon initiates phase I PX-866 trial in patients with solid tumors

Adventrx reports CoFactor phase IIb overall survival results

Obese patients treated with liraglutide for 1 year show significant weight loss

Elan and Wyeth present top-line results from phase II bapineuzumab trial in AD

Lipoxen is granted Canadian approval to initiate phase I trial of ErepoXen for anemia

Takeda requests reexamination of negative opinion for ramelteon given by EMEA's CHMP

Bayer Yakuhin and Mitsubishi Tanabe enter joint marketing agreement for Glucobay

Novel antibacterial agents disclosed in recent Actelion patent

Recent Concert patent reports new anti-HIV agents

Spectrum selects Fusilev as tradename for levoleucovorin for injection

FDA Advisory Committee recommends approval of ustekinumab

Pharming reports positive results from North American trial of Rhucin in HAE

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...